QBECO with growing evidence that innate immune system dysfunction may underlie a variety of autoimmune diseases, Qu Biologics began treating patients with Crohn’s disease, UC and arthritis through a compassionate use program.
Ten (10) patients with uncontrolled persistent moderate to severe CD were treated with QBECO SSI treatment through the compassionate use program. Patients may have continued to receive conventional medical treatments and/or complementary therapies in addition to the SSI treatment.
SEVEN OF THE TEN PATIENTS REPORTED FULL RESOLUTION OF CLINICAL SYMPTOMS WITH A COURSE OF QBECO SSI TREATMENT OF THREE MONTHS OR MORE.
FOUR OF THESE PATIENTS HAVE HAD SUSTAINED CLINICAL REMISSION AFTER DISCONTINUING ALL MEDICATIONS INCLUDING SSI TREATMENT. THE LONGEST CASE OF CLINICAL REMISSION REPORTED IS STILL ONGOING, AFTER ALMOST 3 YEARS.
THREE OF THE SEVEN PATIENTS REPORTING FULL REMISSION HAD FOLLOW-UP COLONOSCOPIES OR CT SCAN WITH CONFIRMATION OF FULL REMISSION. NINE OF THE TEN PATIENTS WERE ABLE TO DISCONTINUE ALL OTHER MEDICATIONS AT SOME POINT WHILE ON QBECO SSI TREATMENT.
It is important to note that data collected were neither placebo-controlled nor ‘blinded’ to the physician or patient. Accordingly, they represent a prospectively-acquired, cumulative, preliminary experience from which proof of benefit of QBECO SSI treatment cannot be established. However, these observations are sufficiently promising to warrant the conduct of a prospective, randomized, placebo-controlled, double-blinded clinical study of QBECO SSI treatment versus placebo in patients with active, moderate to severe Crohn’s disease.
– Read more at: QBECO for the treatment of Crohn’s disease